José Guimarães (JG) has undergone formation in a wide variety of research subjects, allowing him the ability to integrate different sources of information and findings form several distinct scientific research backgrounds and implement novel approaches in the development of his scientific career. JG has completed his bachelor’s (2020) and master’s degree (2022) in Biochemistry at the Faculty of Sciences and the School of Medicine and Biomedical Sciences (ICBAS)-University of Porto. JG’s bachelor’s thesis was developed under the supervision of Prof. Dr. Manuel Vilanova in the Immunobiology group at the Institute for Research and Innovation in Health (i3S). During this period, he focused his studies to address the immunobiological mechanisms operating in hosts infected with the parasite Neospora caninum for the development of a vaccination strategy. As a result of this work, he co-authored a poster presented in the Annual Meeting of the Portuguese Society for Immunology, 2023. During JG’s master’s project, conducted under the supervision of Dr. Clara Pereira in the Yeast Signaling Networks group, also at i3S, he delved into yeast strain manipulation studies to develop a yeast-based screening assay to specifically identify inhibitors of the Hsp90-Cdc37 kinase chaperone complex for potential use in anti-cancer therapy. Currently, JG’s a PhD student enrolled in the biomedical PhD program at the Faculty of Medicine- University of Porto (2023-). He integrates the Intercellular Communication and Cancer research group at i3S , where, under the supervision of Dr. José Carlos Machado, he is focusing his studies to understand the mechanisms underlying the acquisition of resistance to targeted therapies in lung cancer in order to develop novel therapeutic strategies to overcome resistance to treatment. Currently JG is a visiting researcher at the McManus Lab at the Diabetes Center in the University of California, San Francisco, where he is leveraging high-throughput, genome-wide CRISPR screens to decode the molecular communication established between cancer cells. By understanding the exact nature of this interaction, his ultimate goal is to develop novel therapeutic strategies that overcome therapy resistance.